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Abstract: Complexes containing five 4,5-disubstituted-3-mercapto-l,2,4-triazoles ,and Zn(II), Hg(II) and
Cu(I) were synthesized and characterized by standard procedures (elemental analysis; IR, electronic and
NMR spectroscopy, conductimetry and TG analysis). Both the thione as well as the thiolate forms of the
ligands were evidenced to interact with the metal ions in tile prepared complexes. The original mercaptans
and their metal complexes behave as inlfibitors of three carbonic anhydrase (CA) isozymes, CA I, II and IV,
but did not lower intraocular pressure in rabbits in animal models of glaucoma.
Introduction
Carbonic anhydrase (CA, EC 4.2.1.1), an enzyme playing a central role to both transport and
metabolic processes involving CO2 and bicarbonate, is present in a variety of tissues of higher vertebrates in
the form of eight isozymes [2-4]. By catalyzing the reversible interconversion between the two chemical
species mentioned above, in metabolically active tissues (such as the muscle), cytoplasmic (CA I-III) and
sarcolemmal (CA III) isozymes facilitate CO2 transport out of the cell [3]. The only membrane-bound
isozyme known (CA IV), wlfich is higlfly abundant in the kidneys and lungs, lms been shown to possess an
extracellular orientation of the active site, and to be critical in acidifying file outer boundary layer through the
protons formed by CO2 hydration [5,6], a process that then facilitates among others cellular anunonia
transport by providing the I-V ion for the protonation of NH3 and maintaining thus the trans-membrane
anunonia gradient [3,5].
The mitochondrial isozyme (CA V) is known to supply bicarbonate/CO2 for the initial reaction of
gluconeogenesis and ureagenesis in many m,’unmalian tissues [7,8], as well as for tile pyruvate carboxylation
in tile de novo lipogenesis in adipocytes [9].
Aromatic/heterocyclic sulfonamides with tile general formula R-SOzNH2 act as powerful inhibitors
of the above menlioned isozymes [4, 10-16], although relevant differences of ,affinity for these inhibitors
between them have been evidenced [4]. Thus, CA II is the most susceptible to inlfibition by sulfonamides [4],
followed by CA IV and V [6, 9], whereas CA has generally a lower ,nity for this type of inhibitors and a
much larger one (as compared to the previously mentioned isozymes) for the inorganic complexing anions,
such as cyanide, cyanate, thiocyanate [4,17-19]. Endly, CA III is a sulfonamide-resistant isozyme [20], being
appreciably iflfibited only at very large (millimolar) concentrations of inhibitor (the other isozymes may be
inhibited at micromolar nanomolar concentrations of sulfonamides such as acetazolamide 1, benzolamide 2,
ethoxzolmnide 3, dichlorophenamide 4 or dorzolatnide 5 all clinically used drugs [21-24]). The main
application of such agents is as antiglaucona drugs [22-24], but they are also used as ,’mtiulcer [21 ], diuretic
[25], or antiepileptic drugs [26], as well as diagnostic tools in NMR imaging [27, 28]. Although many
sulfonamide CA inhibitors possess high affinity for the major isozymes considered to play important
physiological functions (such as CA II, CA IV and CA V) [4, 7, 8, 11-16], the critical challenge for the
design of novel pharmacological agents from this class, is constituted by the lack of specificity of such
colnpounds towards the different isozymes [4, 29, 30]. Thus, the search of compounds from other classes
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than the sulfonanfides, which might act as powerful inlfibitors of different CA isozymes, is actively involving
several laboratories, ,and interesting results have emerged recently [31 35]. Recently, Christianson’s group
[35] proved that hydroxamate 6 acts as a potent inhibitor of CA II, whereas we have investigated the
interaction of isozymes and II with mercaptans 7 ,and 8, ,and some of their metal complexes [34, 36].
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The powerful inhibition observed with some heterocyclic mercaptans of type 7 ,and 8 [34, 36]
prompted us to extend researches in tlfis class of compounds. In this paper we, report irddbition studies
against CA isozymes I, II ,and IV with five 4,5-disubstituted-3-mercapto-l,2,4-triazoles and their Zn(II),
Hg(II) and Cu(I) complexes, which were synthesized and characterized by standard procedures.
Materials and Methods
IR spectra were recorded on a Perkin-Ehner 16PC FTIR instrmnent, in the range 200-4000 cm1, in KBr
pellets. Solution electronic spectra were recorded with a Cary 3 spectrophotometer interfaced with a PC.
Conductimetric measurements were done in DMF solutions, at 25C (concentrations of mM of complex)
with a Fisher conductimeter. Magnetic susceptibility measurenents were carried out at room temperature
with a fully automated AZTEC DSM8 pendulmn-type susceptometer. Mercury(II) tetrakis-
(thiocyanato)cobaltate(II) was used as a susceptibility standard. Corrections for the di,’unagnetism were
estimated from Pascal’s constants [37]. Elemental analyses were done by combustion for C, H, N with an
automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were + 0.4% of the theoretical
values. NMR spectra were recorded in DMSO-d6 as solvent with a Bruker CPX-200 instrument.
Thennogravimetric measurements were done in air, at a heating rate of 10C/rain., with a Perkin Elmer 3600
thennobalance.
Mercaptans 9-13 were prepared as described in the literature [38]. Metal salts (Cu(I) chloride, Hg(II)
chloride and Zn(II) sulfate pentahydrate), triethylamine and solvents were from E. Merck (analytical grade)
and were used without additional purification.
Human CA and CA II cDNAs were expressed in Escherichia coli strain BL21 (DE3) from the
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plasmids pACA/HCA ,and pACMHCA II (the two plasmids were a gift from Prof. Sven Lindskog, Uxnea
University, Sweden). Cell growth conditions were those described by Lindskog’s group [39] and enzymes
were purified by affinity chromatography according to the method of Khalifah et al. [40]. Enzyme
concentrations were determined spectrophotometric,’flly at 280 nm, using a molar absorptivity of 49 mM-1.
cm
-1 for CA I and 54 mM-l.cm
-1 for CA II, respectively, based on Mr 28.85 kDa for CA I, and 29.3 kDa for
CA II, respectively [41]. CA IV was isolated from bovine lung nficrosomes [42].
hfitial rates of 4-nitrophenyl acetate hydrolysis were mofitored spectrophotometfically, at 400 nm
and 25C, with a Cary 3 apparatus interfaced with an IBM compatible PC by the method of Pocker and Stone
[43]. Solutions of substrate were prepared in anhydrous acetonitrile; the substrate concentrations varied
between 10
.2 and 10
.6 M. A molar absorption coefficient 18,400 Ml.cm
-1 was used for the 4-
nitrophenolate formed by hydrolysis, in flae conditions of the experiments (pH 7.80), as reported by Pocker
and Stone [43]. Non-enzymatic hydrolysis rates were always subtracted from flae observed rates. Duplicate
experiments were done for each inlfibitor, ,and file values reported throughout the paper ,are the averages of
such results. ICso represents the molarity of ilthibitor producing a 50% decrease of enzyme catalyzed
hydrolysis of 4-nitrophenyl acetate.
General procedure for the preparation of the Zn(II) and Hg(II) complexes 14-23
4 mMol of mercaptan 9-13 were suspended in 25 mL MeOH mad 4mMol of Et3N were added in order to
deprotonate the ligand. Tlfis was treated thereafter with a methanolic solution of the metal salt (Zn(II) sulfate
and Hg(II) clfloride, respectively), working at file molar ratios M
2+ mercapt,’m of 1:2. A yellowish-white
precipitate formed inunediately. The obtained reaction mixture was heated on a ste,-un bath for 2 hours, then
the precipitated complexes were filtered, thorouglfly washed with cold alcohol and ,air dried. Crystallization
was not done as the only solvents in which the complexes possessed good solubility were DMSO and DMF.
The obtained powders of complexes 14-23 melted with decomposition at temperatures lfigher than 300 C.
Preparation of the Cu(1) complexes 24-28
An ,’unount of 6 mMol of the ligand 9-13 in 50 mL of absolute ethanol was added to 0.300 g CuC1 (3 mMol)
dissolved in 30 mL of,’ufllydrous acetonitrile. The gelatinous cream-like precipitate was filtrated with suction
and air dried under reduced pressure over silica gel at room temperature. Basically this method used by us is
the stone as the one described by Raper’s group [44-46] for the preparation of Cu(I) complexes of imi&azole
thiones and related lig,’mds.
Results and Discussion
The heterocyclic mercaptans 9-13 used for file preparation of metal complexes, were deprotonated in
the presence of triethylanine prior to complexation with Zn(II) ,and Hg(II),or were used as neutral ligands in
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9-13
the case of the Cu(I) derivatives, as described by Raper’s group for similar ligands [44-46].
One of the main complication which one lms to face when preparing metal conplexes of ligands of
the type used by us in the present work, regards the many tautomeric forms of such compounds [44-46]. As
for the related systems of 1-methylimidazoline-2(3H)-thione, thoroughly investigated by Raper’s group [44-
46] or the 4-mnino-l,4-dihydro-3-methyl-l,2,4-triazole-5-thione investigated by Pellinghelli’s group [47],
colnpounds 9-13 e,’,dfibit the thiol thione tautomerism presented in Scheme 1.
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In the solid state and in neutral solution, the tlfione forms of type B ,are the dominant tautomers, with
the tlfione sulphur atom as the favoured donor site [44-46]. Deprotonation of these derivatives in a variety of
conditions generates thionate mions in which both the tlfionate sulphur as well as the endocyclic nitrogen
atoms are available, either singly or collectively, for coordination. In this work we have used both these
possibilities for preparing metal complexes of derivatives 9-13. Thus, in the case of the Zn(II) and Hg(II)
derivatives, the metal complexes were prepared using the deprotonated derivatives 9-13, whereas the Cu(I)
complexes were obtained from the neutral (thione) form of the ligands, as in the classical studies of Raper’s
group [44-46].
The new complexes 14-28 reported in the present work and their elemental ,analysis data are shown
in Table I.
Table I" Prepared complexes 14-28, containing the mercapto-triazoles 9 13 (LH) or their conjugate bases
(L) as ligands and their elemental analysis data.
No. Complex Ligand Analysis (calculated/found)*
LH %M %C
b %H
b /oN
b
14 [ZnL2] 9 8.6/8.5
15 [ZnL2] 10 7.9/8.1
16 [ZnL2] 11 7.1/6.9
17 [ZxtL2] 12 7.0/7.0
18 [ZL2] 13 8.5/8.1
19 [HgL2] 9 22.5/22.2
20 [HgL2] 10 20.9/20.7
21 [HgL2] 11 19.1 19.1
22 [HgL2] 12 18.8/18.6
23 [HgL2] 13 22.2/22.4
24 [Cu(LH)2CI] 9 8.0/8.1
25 [Cu(LH)2CI] 10 7.4/7.5
26 ICu(LH)2CII 11 6.7/6.6
27 [Cu(LH)2C1] 12 6.5/6.7
28 [Cu(LH)2C1] 13 7.9/7.5
50.9/51.1
46.6/46.4
42.1/41.8
51 5/51.5
43 8/43.5
43 1/43
40.0/40
36.6/36.2
45.0/45.2
37.2/37.0
48.6/48.9
44.7/44.3
40.5/40
49.6/49.2
41 8/41.7
3.7/3.3
3 1/3.3
2.8/2.7
4.0/4.3
2.3/2.2
3 1/2.8
2.7/2.3
2.4/2.5
3 5/3.5
9/1.7
3 8/3.7
3 2/3.2
2.9/2.6
4.1/4.3
2.5/2.2
11.1/10.9
10.2/10.0
9.2/9.0
9.0/8.8
10.9/10.8
9.4/9.4
8.7/8.5
8.0/7.9
7.8/7.5
9.3/9.0
10.6/10.3
9.7/9.6
8.8/8.5
8.6/8.2
10.4/10.0
%y gravimetry: bBy combustion; * No weight loss observed under 200 C by TG mlalysis.
The most important IR bands in the spectra of compounds 9-28 are shown in Table II. Several
important features of flese spectra should be mentioned: (i) the two SO2 vibrations appear mchanged in the
IR spectra of the ligands 9-13 and their met,’fl complexes 14-28, proving flat these moieties do not interact
with fle metal ions (data not shown); (ii) major modifications in the spectra of the complexes as compared to
lhose of the corresponding ligands, regard fle thioamide vibrations (Table II). Thus, with the exception of the
thioanide III band, generally appearing at the same wavelength in the spectra of the lig,’mds and those of the
complexes, fle other tlvee flfioaxnide b,’mds are perturbed by the presence of the metal ions. In the spectra of
complexes, the tlfioamide II and IV bands appeared with 5 45 cm-
at lower wavelength as compared to fle
corresponding band of the ligand, whereas fle thio,-unide band appeared wifl 20-30 cm-
at lfigher
wavelength for the Zn(II) and Hg(II) complexes, and were unchanged for the Cu(I) derivatives. The most
perturbed was the thiomnide IV band, wlfich was generally splitted in two or tlu’ee intense bands in the
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Table II: IR bands and their assignement for derivatives 9-28.
Compounds IR band (cm)
v(NH) Thioanfide I Thioamide II Thioamide III Thioamide IV v(M-X)
9 3090 1480 1280 1090 770
14 1500 1275 1090 750,800 440,590
19 1500 1280 1090 740,800 415,540
24 3090 1480 1270,1285 1090 730,745,790
10 3085 1470 1275 1090 775
15 1500 1270 1090 740,790 435,590
20 1500 1270 1090 730,800 415,545
25 3085 1470 1260,1280 1090 725,750,785
11 3080 1470 1280 1075 760
16 1500 1270 1075 745,780 430,600
21 1495 1270 1070 750,780 410,550
26 3080 1470 1270,1285 1080 730,745,775
12 3090 1475 1280 1085 775
17 1500 1260 1080 735,790 440,580
22 1500 1260 1085 730,780 410,550
27 3090 1475 1265,1290 1080 730,750,785
13 3290 1470 1280 1080 770
18 3260 1500 1275 1080 725,785 445,600
23 3260 1500 1270 1080 725,790 415,540
28 3290 1470 1260,1285 1080 725,755,790
M-S or M-N vibrations.
spectra of all metal complexes, whereas in the spectra of the ligands it was presented as a single band. This
behaviour has been previusly reported for other metal complexes of heterocyclic thiones [44-46]; (iii) a clear
distinction could be made regarding the tautomeric form of the ligand in the case of the Zn(II) and Hg(II)
complexes on one hand, and the Cu(I) derivatives on the other hand. Thus, for the first derivatives (prepared
from the deprotonated form of the ligand) no NH bands were evidenced in the IR spectra (these bands were
present in the spectrum of the corresponding ligand), whereas for the Cu(I) derivatives these arre present at
the stone frequencies as in the case of the ligand. The thio,-unide band is ,also different for the two groups of
complexes, with the Cu(I) derivatives showing this band at the same frequency as in the case of the ligand,
whereas for the Zn(II) and Hg(II) derivatives the correponding band was shifted at higher wavelength. The
thioamide II band on the other hand was splitted only in the case of the Cu(I) derivatives. In the H- and 3C-
MR data of the Hg(II) complexes, the following modifications have been noted as compared to the
corresponding spectra of the original mercaptans 9-13: (i) the signal of the NH proton, appearing at 8.30
8.35 ppm in the H-NMR spectra of colnpounds 9-13, is absent in the spectra of the corresponding Zn(II) and
Hg(II) complexes, 14-23; (ii) other signals (the arolnatic protons, the lnoiety substituting the N-4 atom)
appear in the same ranges in the original mercaptans and the corresponding Zn(II) and Hg(II) coxnplexes
(data not shown); (iii) in the 3C-NMR spectra, the C-3 carbon atoms show a signal at 168.2 168.6 ppm in
the spectra of compounds 9-13, whereas in the spectra of the corresponding Zn(II) and Hg(II) complexes
these signals appear at 165-167 ppm. This sltift is presumably due to the presence of the coordinated metal
ions in the neighbourhood of these atoms; (iv) other sigqals in the C-NMR spectra of xnercaptans 9-13 and
metal complexes 14-23 appear tmchanged, at the same chemical shifts (data not shown). All the prepared
complexes showed no weight loss under 200C, were non-electrolytes (in DMF as solvent, at room
temperature data not shown), diamagnetic (data not shown) and colorless also in the case of the Cu(I)
derivatives, prompting us to propose the stnctures shown below. All these data indicate that in the case of
the Zn(II) and Hg(II) derivatives the ligand acts in deprotonated form, bidentately, with the donor system
probably constituted by the endocyclic xfitrogen and the mercaptide sulfur atoms. In the case of the Cu(I)
derivatives, the thione form of the ligands probably acts monodentately, with the thione sulfur as donor atom,
similarly as in the Cu(I) derivatives of 1-methylimidazoline-2(3H)-thione reported by Raper’s group [44-46].
The Cu(I) derivatives are probably dimers, as the similar complexes reported by Raper’s group [44-46].
Inlfibition data against tltree CA isozymes, CA I, II (cytosolic) and IV (membrane-bound) with
compounds 9-28 and standard inlfibitors are shown in Table III.
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Tile following facts should be noted regarding CA iflffbition with tiffs type of iflfibitors: (i) whereas
the mercaptmls 9-13 behave as moderate inlfibitors against all flvee isozymes investigated here, their metal
complexes act as potent inlfibitors, similarly to file unsubstituted sulfon,’unides 1-3 with clifical applications.
The most efficient inhibitors were fle Hg(II) complexes, followed by the Cu(I) derivatives ,and fle Zn(II)
complexes; (ii) in fle series of mercaptans 9-13 as well as for the correponding complexes, fle most active
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Table III: CA irdffbition data with st,’m&d irdffbitors and compounds 9-2.
Compound IC5o (nM)*
hCA hCA II bCA IV
b
1 (acetazolamide) 200+4 7+0.2 120+9
2 (benzolamide) 10+1 2+0.5 8+0.3
3 (ethoxzolamide) 8_+0.9 2+0.2 4+0.2
9 1200+60 189+5 170+6
10 1130+20 175+4 160+7
11 1040+30 162+4 160+2
12 1560+45 210+8 194+10
13 870+12 96+8 121+11
14 160+2 45+3 130+5
15 150+3 33+2 125+3
16 110+2 30+1 124+8
17 387+5 190+0.6 245+2
18 67+6 15+1 27_+1
19 12_+2 3 _+0.1 6_+0.7
20 10+0.9 3+0.3 6+0.9
21 8+0.4 2+0.2 4+0.2
22 230-+8 150_+9 180_+5
23 3_+0.3 0.5_+0.1 3_+0.1
24 16_+1 5_+0.1 7_+0.1
25 14_+1 4+1 9+0.2
26 6-+1 4+0.7 5+0.6
27 307-+5 167_+12 215+10
28 4_+0.1 0.8_+0.1 1+0.1
16
* Mean -+ average spread (frown two determinations).
aHuman (cloned) isozyme; bIsolated from bovine hmg microsomes.Andrea Scozzafava, Christine Cavazza et al. Metal-Based Drugs
iflfibitors were those possessing an N-Et or NH moiety in the 4 position of the heterocyclic ring, whereas the
compounds possessing N-cyclohexyl such groups had a largely decreased affinity for the enzyme,
presumably due to steric hindrance induced by the bulky cyclohexyl group: (iii) the susceptibility of the
different CA isozymes to inhibition with tlfis class of derivatives was: CA II > CA IV > CA I, being similar
to that for the aromatic/heterocyclic sulfonamides [4].
The newly prepared complexes as well as the heterocyclic mercaptans 9-13 were tested for their
ability to lower intraocular pressure (IOP) in rabbits, in animal models of glaucoma, since recently it was
discovered by this group that metal complexes of heterocyclic sulfonamides act as efficient IOP lowering
agents [48-49]. None of these derivatives showed any effect when applyed as a 2% solution (in DMSO)
directly into the rabbit eye.
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